Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $38.04 USD
Change Today -0.26 / -0.68%
Volume 17.5M
BAX On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 8:04 PM 07/6/15 All times are local (Market data is delayed by at least 15 minutes).

baxter international inc (BAX) Snapshot

Open
$38.15
Previous Close
$38.30
Day High
$38.41
Day Low
$37.75
52 Week High
07/23/14 - $42.00
52 Week Low
06/9/15 - $34.77
Market Cap
20.7B
Average Volume 10 Days
12.5M
EPS TTM
$4.38
Shares Outstanding
544.3M
EX-Date
05/28/15
P/E TM
8.7x
Dividend
$2.08
Dividend Yield
5.47%
Current Stock Chart for BAXTER INTERNATIONAL INC (BAX)

baxter international inc (BAX) Related Businessweek News

View More BusinessWeek News

baxter international inc (BAX) Details

Baxter International Inc., develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company’s BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; and biosurgery products. The Medical Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics; and products and services related to pharmacy compounding, drug formulation and packaging technologies, as well as to treat renal disease, irreversible kidney failures, and other renal therapies. This segment also offers products for peritoneal dialysis, in-center and home hemodialysis, continuous renal replacement therapy, and other dialysis services. It markets its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy to hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, clinical and medical research laboratories, and patients. The company operates in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Latin America, and Canada. It has collaboration with Merrimack Pharmaceuticals, Inc. to develop and commercialize MM-398 injection; CTI BioPharma Corp. to develop and commercialize pacritinib; Coherus Biosciences, Inc. and Momenta Pharmaceuticals, Inc. to develop and commercialize biosimilars; JW Holdings Corporation for parenteral nutritional products; and Onconova Therapeutics, Inc. for rigosertib anti-cancer compound. The company was founded in 1931 and is based in Deerfield, Illinois.

66,000 Employees
Last Reported Date: 02/26/15
Founded in 1931

baxter international inc (BAX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer and Corporate Vice Pr...
Total Annual Compensation: $755.0K
Corporate Vice President and President of Bio...
Total Annual Compensation: $833.8K
Corporate Vice President, General Counsel and...
Total Annual Compensation: $651.0K
Corporate Vice President of Human Resources
Total Annual Compensation: $525.3K
Compensation as of Fiscal Year 2014.

baxter international inc (BAX) Key Developments

Baxter International Inc.(NYSE:BAX) dropped from S&P 100 Index

Baxter International Inc.(NYSE:BAX) dropped from S&P 100 Index

Kamada Announces New Collaboration with Baxter's Unit for Lung-Transplant Treatment Study

Kamada Ltd. reported it has entered into a collaboration agreement for its phase 1/2 clinical trial of its proprietary alpha-1 antitrypsin treatment for the prevention of lung transplant rejection with Baxter International's Baxalta International subsidiary. Under the terms of the agreement, Baxalta will collaborate in the development and funding of the study, which is expected to begin in the first half of 2016 in Israel. Financial terms of the agreement weren't disclosed.

Baxter International Inc. Commences Two Cash Tender Offers for Specified Series of its Outstanding Debt

Baxter International Inc. announced that it has commenced two cash tender offers for specified series of its outstanding debt. The terms and conditions of the Tender Offers are described in Baxter's offer to purchase and the related Letter of Transmittal, each dated June 19, 2015. The tender offers consist of two separate offers: an any and all tender offer and a maximum tender offer, both made pursuant to the Offer to Purchase, which sets forth a comprehensive description of the terms of each of the Tender Offers. In the Any and All Tender Offer, Baxter is offering to purchase any and all of the five series of notes listed in the table below. In the Maximum Tender Offer, Baxter is offering to purchase, subject to the maximum tender amount described below and any resulting proration, the notes of the series listed below in the preferential order of the acceptance priority levels identified in the table below. Per/$1,000 principal amount of notes validly tendered and accepted for purchase, which amount includes an early tender payment of /$30. Does not include accrued interest, which will be paid on notes, accepted for purchase. This represents the hypothetical Total Consideration for each series of notes, other than the 2042 notes, and is calculated based on a yield to the maturity date for each applicable series of notes. Actual Total Consideration for the 2042 Notes. Baxter is offering to purchase the maximum aggregate principal amount of notes in the Maximum Tender Offer that it can purchase (including accrued interest) for up to the positive difference (if any) between /$3.0 billion and the total consideration that is paid (including accrued and unpaid interest) for the notes purchased through the Any and All Tender Offer. The acceptance of any tendered notes subject to the Maximum Tender Offer may be subject to proration, as described in the Offer to Purchase. Baxter reserves the right in its sole discretion to increase the Maximum Tender Offer cap. Baxter currently intends to redeem such amount of notes subject to the Maximum Tender Offer and/or 5.900% Notes due September 2016 so that the sum of the aggregate redemption price of notes subject to the Maximum Tender Offer or 2016 Notes redeemed in the redemption (including accrued and unpaid interest) and the aggregate amount paid to acquire all notes accepted for purchase pursuant to both Tender Offers (including accrued interest) equals approximately /$3.0 billion in the aggregate. However, Baxter is not obligated to undertake any such redemption, and there can be no assurance that Baxter will redeem any notes subject to the Maximum Tender Offer or 2016 Notes that remain outstanding after consummation of the Tender Offers or of the timing of, or amount of any notes subject to the Maximum Tender Offer and/or 2016 Notes subject to, any such redemption. The Any and All Tender Offer is scheduled to expire at 11:59 p.m., New York City time on July 16, 2015, unless extended or earlier terminated by Baxter at its sole discretion. Holders of notes subject to the Any and All Tender Offer must validly tender and not validly withdraw their notes at or prior to 5:00 p.m. NYC time on July 1, 2015, unless extended or earlier terminated by Baxter at its sole discretion, to be eligible to receive the applicable total consideration, which includes an early tender payment of /$30 per /$1,000 principal amount of notes validly tendered and accepted for purchase. Holders of notes subject to the Any and All Tender Offer who tender their notes after the Any and All Early Tender Time and at or prior to the Any and All Expiration Time, will be eligible to receive the applicable tender offer consideration, which is the total consideration minus the early tender payment. Holders of notes subject to the Any and All Tender Offer may not withdraw their tendered notes after the Any and All Early Tender Time, subject to applicable law. The Maximum Tender Offer is scheduled to expire at 11:59 p.m. NYC time on July 16, 2015, unless extended or earlier terminated by Baxter, at its sole discretion. Holders of notes subject to the Maximum Tender Offer must validly tender and not validly withdraw their notes at or prior to 5:00 p.m. NYC time on July 1, 2015, unless extended or earlier terminated by Baxter at its sole discretion, to be eligible to receive the applicable total consideration, which includes the early tender payment. Holders of notes subject to the Maximum Tender Offer who tender their notes after the Maximum Early Tender Time and at or prior to the Maximum Tender Expiration Time, will be eligible to receive the applicable tender offer consideration, which is the total consideration minus the early tender payment. The applicable total consideration or tender offer consideration will only be paid to holders of tendered notes that are subject to the Maximum Tender Offer to the extent that Baxter accepts such notes for purchase. Holders of notes subject to the Maximum Tender Offer may not withdraw their tendered notes after the Maximum Early Tender Time, subject to applicable law. The total consideration for each /$1,000 principal amount of notes, other than the 3.650% Notes due 2042, validly tendered and accepted for purchase pursuant to the Tender Offers will be determined in the manner described in the Offer to Purchase by reference to a fixed spread specified for each series of notes over the yield based on the bid side price of the U.S. Treasury Security specified for each series of notes on the front page of the Offer to Purchase or in the table above, as calculated by Goldman, Sachs & Co. and BofA Merrill Lynch at 2:00 p.m. NYC time on July 1, 2015, for the Any and All Tender Offer, and 2:00 p.m. NYC time on July 1, 2015, for the Maximum Tender Offer. The actual total consideration for each /$1,000 principal amount of 2042 notes validly tendered at or prior to the Any and All Early Tender Time and accepted for purchase pursuant to the Any and All Tender Offer is specified in the table above. In addition to the total consideration or the tender offer consideration, as applicable, accrued and unpaid interest on the purchased notes will be paid from the appli cable last interest payment date to, but not including, the applicable settlement date for such purchased notes. Payment for notes tendered at or prior to the Any and All Early Tender Time and purchased in the Any and All Tender Offer will be made promptly after the Any and All Early Tender Time, if the Any and All Tender Offer is not extended or earlier terminated. Payment for the notes tendered after the Any and All Early Tender Time and purchased in the Any and All Tender Offer will be made promptly after the Any and All Expiration Time, if the Any and All Tender Offer is not extended or earlier terminated.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BAX:US $38.04 USD -0.26

BAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $17.55 USD -0.02
Cerner Corp $68.23 USD -0.25
Fresenius Medical Care AG & Co KGaA €73.25 EUR -0.66
St Jude Medical Inc $73.05 USD +0.02
Zimmer Biomet Holdings Inc $108.79 USD +0.60
View Industry Companies
 

Industry Analysis

BAX

Industry Average

Valuation BAX Industry Range
Price/Earnings 11.3x
Price/Sales 1.3x
Price/Book 2.9x
Price/Cash Flow 8.8x
TEV/Sales 0.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAXTER INTERNATIONAL INC, please visit www.baxter.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.